New name, but same old problems for Posimir as FDA hits Durect again

Ben Adams Durect may have changed the name of its post-pain gall bladder surgery drug from "Posidur" to "Posimir" this year, but this has not stopped its run of ...

Pfizer investors stand with CEO Read even though he is 0 for 2 on megamergers

Eric Palmer Pfizer CEO Ian Read walked away from its $ 160 billion merger with Allergan this week after U.S. Treasury Department rule changes sucked the value out of its tax inversion ...

Pfizer pulls thousands of bottles of children’s and infants’ Advil in Canada

Eric Palmer Parents needing to treat their children during this cold season are facing another hurdle after Pfizer pulled 126 lots of children's and infants' Advil products ...

U.K. keeps funding for clinical research sites flat through to 2022

Nick Paul Taylor The United Kingdom government is to pump £112 million ($ 160 million) into a network of clinical research facilities from 2017 to 2022. Officials see the investment ...

Replacing a biotech legend, Gilead’s new CEO inherits sky-high expectations

Damian Garde John Martin, the man who led Gilead Sciences from the basements of biotech to the verge of Big Pharma, is stepping down after 20 years, with longtime lieutenant John Milligan ...

Struggling Eisai gets FDA approval for cancer drug Halaven for liposarcoma

Eric Palmer Japan's Eisai got a much-needed boost on Thursday when the FDA approved its cancer drug, Halaven, for treatment of liposarcoma for patients in which the cancer has advanced ...

Lilly, BI approach CV-benefit label change for SGLT2 med Jardiance

Carly Helfand Eli Lilly and Boehringer Ingelheim are one step closer to an important label change for SGLT2 contender Jardiance. FiercePharma News

U.K. cost watchdog nixes pricey biologics for moderate rheumatoid arthritis

Carly Helfand The U.K.'s cost effectiveness gatekeepers are giving their final blessing to a slew of rheumatoid arthritis biologics–but only for patients with advanced forms ...

J&J loses bid to dismiss false advertising lawsuit over baby products

Carly Helfand Johnson & Johnson was hoping to put a marketing case around its Bedtime Products for babies to rest, but a federal judge isn't having it. FiercePharma News

GSK, AstraZeneca and J&J back $57M effort to springboard university drug research

John Carroll Three of the U.K.'s leading universities are joining hands with three of the world's biggest pharma giants to create a new translational medicine group aimed at ...

Merck teams with Affimed on immuno-oncology combo

John Carroll Germany’s Affimed has inked a deal that makes it the latest in a long string of biotechs to partner up with Merck on a combination study using the PD-1 blockbuster ...

Shkreli’s 5th Amendment hall pass rejected for congressional drug pricing hearing

Emily Wasserman Pharma bro Martin Shkreli is requesting a hall pass to get out of testifying at a congressional hearing on drug pricing next week after receiving a subpoena ordering ...
Page 1 of 12912345...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS